Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Desde el perfilado de microARN hasta la industrialización de nuevas herramientas de toma de decisiones en diagnóstico in vitro

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOFR20160603001
Publicado:
07/07/2016
Caducidad:
07/07/2017
Resumen:
Una empresa francesa ha desarrollado una plataforma de identificación de biomarcadores de microARNs circulantes y tisulares para investigación aplicada y fines de diagnóstico y monitorización de bioterapias. Los microARNs son biomarcadores prometedores para pronóstico de enfermedades, diagnóstico temprano, estratificación de pacientes y pronóstico de recaída, así como las herramientas ideales para medir la eficacia del tratamiento. La empresa busca un socio farmacéutico en el campo de oncología o enfermedades autoinmunes con el fin de establecer acuerdos de investigación y cooperación técnica.

Details

Tittle:
From microRNA profiling to industrialization of innovative IVD decision-making tools
Summary:
French company developed a R-Y-D platform specialized in the identification of circulating and tissue- microRNA biomarkers for applied research to diagnostic purposes and monitoring of biotherapies. MicroRNAs are promising biomarkers for disease outcome prediction, early diagnostic, patients stratification, prognosis of relapse and ideal tools to measure treatment efficacy. They are looking for pharmaceutical partner in oncology or auto immune disease for research, technical cooperation agreement.
Description:
The French company´s molecular platform develops and industrializes tissue- or blood-based microRNAs kits for the diagnosis and monitoring of treatments in oncology, auto-immune diseases and Human Immuno deficiency Virus (HIV)/ Acquired Immune Deficiency Syndrome (AIDS). The company is seeking for partners from R-Y-D to industrialization of innovative microRNA (RiboNucleic Acids) kits.

From discovery to validation of microRNAs biomarkers, this platform offers molecular solutions based on TaqMan® microRNA Assays (TLDA (Taqman Low Dendity Array), Lifetechnologies) that show unrivaled sensitivity, specificity, and dynamic range.

They develop IVD (In-Vitro Diagnostic) products according to the best development practices: Experiment design, microRNA extraction and purification, microRNA profiling.
In this critical step, the company has implemented an "in house" statistical workflow dedicated to the circulating microRNAs.

Samples profiling by high throughput quantitative RT-PCR (within 2 hours), for circulating and intracellular microRNAs quantifications is performed on TLDA technology (Taqman). It allows simultaneous detection from 760 to 1500 (custom) microRNAs per sample. This step is fully automated on the Applied Biosystems viiA7 platform (Lifetechnologies).

The standardized R-Y-D procedures insure the normalization of the results through the implementation of a statistical analysis process. The developed tools enable a simple interpretation of the results through a decision-making score.

The company is ISO 9001: 13485 by the LNE/ G-MED certifying body. They applied a quality management system embodying the most structured norm in IVD industry regarding quality assurance and risk management.

They provide a control of the chain value in the commercialization of innovative diagnostic kits andtheir distribution network is based on reliable partners.

This French industrial company has developed innovative tests based on microRNA signatures. This strategy is in full line with the expectation to rapidly expand a portfolio of new products dedicated to personalized medicine in oncology or auto-immune diseases.

They are looking for companies or R-Y-D institution for technical or research cooperation agreement. Co-operation expectations are:
- Building new partnerships with pharmaceutical companies for the stratification of patients prior their enrolment in clinical trials.
- New scientific collaboration with academics, or hospitals.
Advantages and Innovations:
- Non-invasive for the patient: the test is performed from a simple blood uptake.
- Easy to use and to implement: the test is based on a basic RT-qPCR assay. This technology is commonly used in clinical laboratories and requires no specific training.
- Fast: the analytical step is performed within 4 hours and the results interpreted within a few minutes by using a dedicated algorithm.
- Industrial development, manufacturing -Y- CE marking
Stage of Development:
Under development/lab tested
IPs:
Patents granted
CommeR Statunts Regarding IPR Status:
The company has claimed industrial property rights for the innovative molecular signature discovery in the field colorectal cancer, HIV and LncRNAs

Partner sought

Type and Role of Partner Sought:
- Type of partner sought :pharmaceutical partner
- Specific area of activity of the partner : oncology, auto immune disease
- Task to be performed by the partner sought :select appropriate patient cohorts for microRNA screening and biological validations

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
French

Keywords

Technology Keywords:
06002002 Biología celular y molecular
06001003 Citología, cancerología, oncología
06001005 Diagnósticos, diagnosis